Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CMS To Help Build National FDG-PET Cancer Registry, Will Cover Trials

This article was originally published in The Gray Sheet

Executive Summary

CMS plans to work with stakeholders to develop a national registry as well as small studies to determine the clinical utility of FDG-PET in the management of brain, ovarian, pancreatic and small-cell lung cancers

You may also be interested in...



Informed Consent Issues Proving Tricky In CMS Evidence-Development Policy

Issues surrounding informed consent appear to be complicating CMS' efforts to finalize a policy allowing it to require evidence collection as a condition of national Medicare coverage

Informed Consent Issues Proving Tricky In CMS Evidence-Development Policy

Issues surrounding informed consent appear to be complicating CMS' efforts to finalize a policy allowing it to require evidence collection as a condition of national Medicare coverage

McClellan Expounds On Medicare National Coverage Registry Requirements

The Institute of Medicine is facilitating CMS and industry dialogue on postmarket data collection requirements for national coverage decisions

Related Content

UsernamePublicRestriction

Register

MT021135

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel